title: Emerging immunotherapy in pediatric lymphoma.
abstract: Hodgkin and non-Hodgkin lymphoma collectively are the third most common cancer diagnosed in children each year. For children who relapse or have refractory disease, outcomes remain poor. Immunotherapy has recently emerged as a novel approach to treat hematologic malignancies. The field has been rapidly expanding over the past few years broadening its armamentarium which now includes monoclonal antibodies, antibody-drug conjugates and cellular therapies including bispecific T-cell engagers and chimeric antigen receptor-engineered T cells. Many of these agents are in their infancy stages and only beginning to make their mark on lymphoma treatment while others have begun to show promising efficacy in relapsed disease. In this review, the authors provide an overview of current and emerging immunotherapies in the field of pediatric lymphoma.
authors.affiliation: Division of Pediatric Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
authors.forename: Craig
authors.initials: C
authors.lastname: Erker
authors.affiliation: Division of Pediatric Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Harker-Murray
authors.affiliation: Division of Pediatric Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Burke
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D064987:Cell- and Tissue-Based Therapy; D002648:Child; D002675:Child, Preschool; D015316:Genetic Therapy; D006801:Humans; D056747:Immunomodulation / Q000187:drug effects; D007167:Immunotherapy / Q000379:methods; D000922:Immunotoxins / Q000494:pharmacology / Q000627:therapeutic use; D007223:Infant; D007231:Infant, Newborn; D008223:Lymphoma / Q000276:immunology* / Q000628:therapy*; D058990:Molecular Targeted Therapy; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000637:transplantation
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000922:Immunotoxins
keywords: Hodgkin lymphoma; checkpoint inhibitors; immunotherapy; non-Hodgkin lymphoma; pediatric